Skip to main content

Dimension Bio

Application1375 W Fulton St, Suite 500, Chicago, IL 60607, USAFounded 2017· One of 381 Application companies tracked by AMPulse

Biotechnology company pioneering regenerative therapeutics using BioNidum™ bioinspired cell delivery system combining materials science, 3D-printing, and digital manufacturing to create tissue therapeutics that restore organ function lost to disease, trauma, or aging.

CEO / Founder
Caralynn Nowinski Collens
Team Size
11-50
Stage
Active
Total Funding
$15.4M
Latest Round
Series A
Key Investors
Prime Movers Lab (Series A lead); KdT Ventures (Seed lead); Alumni Ventures; Satori Capital; Prithvi Ventures; Ravelin Capital; B Capital Group; Incisive Ventures; Negev Capital; Parkway VC; Pioneer Fund; Revolution (Rise of the Rest Seed Fund); Solas BioVentures; Portal Innovation Ventures

Technology & Products

Key Products

BioNidum™ System (bioinspired cell delivery platform), tissue therapeutics pipeline targeting liver failure, CMFlex™ (FDA-cleared synthetic bone graft)

Technological Advantage

BioNidum™ bioinspired cell delivery system enables high-density cell loading with three-dimensional architecture promoting rapid vascularization; established GMP manufacturing process; FDA-cleared biomaterial foundation with fully established manufacturing capabilities enabling rapid advancement to clinic.

Differentiation

Value Proposition

Transforms cells into implantable, tissue-like therapies through BioNidum™ bioinspired cell delivery system, providing three-dimensional architecture that promotes rapid vascularization and seamless tissue integration for more durable and effective therapeutic responses in regenerative medicine.

How They Differentiate

Unique biomaterial scaffolds demonstrating rapid vascularization, resistance to foreign body response, and natural affinity for cells; BioNidum™ platform transforms cells into implantable tissue-like therapies; established GMP manufacturing with clear clinical path in liver therapeutics; FDA-cleared CMFlex™ validates underlying biomaterials platform.

Market & Competition

Target Customers

Orthopedic and reconstructive surgeons; medical device OEMs; regenerative medicine companies

Industry Verticals

Regenerative medicine; Liver therapeutics; Cell therapy; Biotech/pharma; Tissue engineering

Competitors

Cellink, Aspect Biosystems, Precise Bio, Organovo Holdings, Inc., Allevi, Prellis Biologics, CollPlant.

Growth & Milestones

Growth Metrics

Rebranded to Dimension Bio (May 2025); BioNidum™ System in use across multiple therapeutic products including one clinical-stage product; lead liver failure program advancing with preclinical data presented at AASLD 2025; commercialization resource awards from ReGen Valley Tech Hub (Aug 2025); Chicago Innovation Awards winner (2024); Fast Company Innovation by Design Awards finalist (2024).

Major Milestones

[object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]; [object Object]

Notable Customers

Clinical and scientific advisory boards with leading liver disease specialists; partners with three partnered products in development using BioNidum System; continuing CMFlex™ synthetic bone graft commercialization

https://dimension.bio

Why this company matters

Dimension Inx occupies a unique position at the intersection of additive manufacturing and regenerative medicine. While most bioprinting companies remain in preclinical or research stages, Dimension Inx has achieved FDA 510(k) clearance for CMFlex, a synthetic bone graft produced via its proprietary 3D-Painting platform. This clearance, combined with first surgical cases in Q4 2023, gives the company a commercial foothold that competitors such as Cellink, Aspect Biosystems, and Organovo have not yet matched in orthopedics.

The core technology is a materials-centric platform that combines extrusion-based bioprinting (MEX) with high-loading bioactive ingredient capability. The 3D-Painting System enables precise control over microarchitecture and material composition, producing scaffolds that mimic trabecular bone structure. Unlike conventional molded or sintered grafts, which require months of lead time, Dimension Inx can manufacture off-the-shelf implants in days using Desktop Health's 3D-Bioplotter hardware. The company's patent portfolio covers the printing system and hydrogel-based biomaterial compositions in the US, Japan, and Australia.

Target customers include orthopedic and reconstructive surgeons, medical device OEMs, and regenerative medicine companies. CMFlex is distributed through a partnership with Desktop Health, and the company also offers custom biomaterial solutions via collaboration with Merz Biomaterials and Advanced Solutions Life Sciences. The addressable market spans bone void filling, spinal fusion, and craniomaxillofacial reconstruction, where synthetic grafts compete with autografts and allografts.

Dimension Inx's strategic moat rests on its FDA clearance, vertical integration from R&D through manufacturing, and surgeon relationships established during early clinical cases. The company raised $15.4 million from investors including Prime Movers Lab and KdT Ventures, with a $12 million Series A closing in February 2023. Key risks include scaling production to meet hospital demand, competition from established orthopedic implant manufacturers entering additive manufacturing, and the need to expand indications beyond bone graft to other tissue types.